Biotech Stock Pre-Market Updates

What are the key pre-market updates for biotech stocks? Galmed Pharmaceuticals (NASDAQ: GLMD) announced it has signed a binding term sheet with Entomus s.r.o. for a license agreement to develop and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS) that enables sublingual abso Portage Biotech (NASDAQ: PRTG) reported confirmatory preclinical data showing that PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor, outperformed anti-PD1 antibody treatment in a murine mesothelioma model. The combination of PORT-7 a CG Oncology (NASDAQ: CGON) announced that Phase 3 BOND-003 Cohort C data for cretostimogene grenadenorepvec monotherapy was presented at the 2025 AUA Annual Meeting. In high-risk NMIBC patients unresponsive to BCG, the study showed a 75.5% comp Merck KGaA (NYSE: MRK) and SpringWorks Therapeutics (NASDAQ: SWTX) announced a definitive agreement for Merck KGaA to acquire SpringWorks for US$47 per share in cash, valuing the company at approximately US$3.9bn in equity and US$3.4bn in enter Biohaven (NYSE: BHVN) announced an agreement with Oberland Capital Management LLC for an investment of up to US$600m, with an initial US$250m tranche set to be funded by 30 April 2025. ADMA Biologics (NASDAQ: ADMA) announced FDA approval of its innovative yield enhancement production process. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma vo